MiniGo™ BioInjector
Formulation Freedom
Let the therapy lead. MiniGo follows.
MiniGo is designed to support the therapy as dose, concentration, viscosity and volume evolve—without forcing a transition to a fundamentally different delivery architecture.
Optimize the therapy rather than yield to device constraints.
Biologics have evolved – Delivery Architecture has not
Convergence toward Optimal Treatment is occurring without delivery architecture response
(Until Now). Legacy based systems compete for relevance in shrinking slices across the dose range need, resulting in unnecessary category segmentation.
Big strides in therapy format, extend to new heights with MiniGo
Conventional “Autoinjector” Economics.
MiniGo was engineered from the outset with manufacturability, scalability and commercial competitiveness in mind. Its simplified platform architecture achieves unit-cost economics that compete with conventional autoinjector technologies.
The true economics extend beyond device cost—to manufacturing efficiency, packaging, logistics, patient preference, persistence and commercial differentiation.
OmniDrive™
makes it all possible.
One architecture supports therapy development needs from lab to clinic to home self administration, adjusting to formulation requirements as they evolve.
What is OmniDrive?
OmniDrive is the novel and patented power-pack and flow-path system behind MiniGo. OmniDrive works differently, without dependency on high input force plunger push techniques. It leverages working pressure relocation and isolation to dramatically reduce the level of input forces required. OmnDrive self-adjusts power delivery as resistances change, providing self-regulating functionality never seen in an economically and ecological efficient all mechanical form. The result is better support across large variations in volume-concentration-viscosity dose payloads without requiring reconfiguration or accepting costly trade-offs.
One Platform. Built for the Future.
Common Architecture · Flexible Configuration · Pharma-Ready Brand Expression
The End of
Autoinjector & Wearable Injectors as we know them.
MiniGo blends capabilities traditionally served by multiple injector categories into one standardized platform. As a unified injector, it is designed to support a broader range of dose, volume and viscosity requirements without requiring a fundamentally different device as the therapy evolves. It is purpose-built to remove delivery constraints from therapies and let them be all they can be for patients.
One Platform. Two Ways to Administer.
Handheld with Stabilizing Assist
(shorter injections <30sec)
Full Hands-Free Operation
(longer injections, 3-5min)
Never too fast – Not unnecessarily long. MiniGo is task focused on delivering your life changing medicines to patients more easily, reliably, and efficiently.
Let’s explore how MiniGo can enhance your therapy.
MiniGo is a device under development by Synolus Medical, Inc. and has not received a marketing authorization from the U.S. Food and Drug Administration (FDA). MiniGo is not offered for commercial distribution, and use of MiniGo on or in humans is strictly prohibited except within an authorized clinical investigation conducted in accordance with applicable law.